Management of ovarian dysfunctions requires accurate estimation of ovarian reserve (OR). Therefore, reproductive hormones and antral follicle count (AFC) are assessed to indicate OR. Serum anti-Mullerian hormone (AMH) is a unique biomarker that has a critical role in folliculogenesis as well as steroidogenesis within ovaries. Secretion from preantral and early antral follicles renders AMH as the earliest marker to show OR decline. In this review we discuss the dynamics of circulating AMH that remarkably vary with sex and age.As it emerges as a marker of gonadal development and reproductive disorders, herewe summarize the role ofAMH in female reproductive physiology and provide evidence of higher accuracy in predicting ovarian response to stimulation. Further, we attempt to compile potential clinical applications in children and adults. We propose that AMH evaluation has a potential role in effectively monitoring chemotherapy and pelvic radiation induced ovarian toxicity. Furthermore, AMH guided ovarian stimulation can lead to individualization of therapeutic strategies for infertility treatment. However future research on AMHlevels within follicular fluid may pave the way to establish it as a marker of "quality" besides "quantity" of the growing follicles.
Jamil, Z., Fatima, S. S., Ahmed, K., & Malik, R. (2016). Anti-Mullerian Hormone: Above and beyond Conventional Ovarian Reserve Markers. Disease Markers. Hindawi Limited. https://doi.org/10.1155/2016/5246217